Reform Proposal Signals Perception Gap between Industry, Govt on Purpose of Market Expansion Re-Pricing

The Central Social Insurance Medical Council (Chuikyo) has wrapped up its first round of debates for the FY2024 drug pricing reform, with discussion points now identified. One of the most interesting topics so far is the Drug Pricing Organization’s (DPO)...read more